{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:54:17Z","timestamp":1790171657185,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Impuls and Vernetzungs-Fonds der Helmholtzgemeinschaft"},{"name":"Impuls and Vernetzungs-Fonds der Helmholtzgemeinschaft"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","neuropeptidesjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.npep.2017.11.011","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T13:46:56Z","timestamp":1511790416000},"page":"27-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A\u03b2 oligomer eliminating compounds interfere successfully with pEA\u03b2(3\u201342) induced motor neurodegenerative phenotype in transgenic mice"],"prefix":"10.1016","volume":"67","author":[{"given":"Tina","family":"Dunkelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Teichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Ziehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schemmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0530-7469","authenticated-orcid":false,"given":"Markus","family":"Tusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Josef","family":"Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Demuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim Jon","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Kutzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Willuweit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-7366","authenticated-orcid":false,"given":"Dieter","family":"Willbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.npep.2017.11.011_bb0005","doi-asserted-by":"crossref","first-page":"12790","DOI":"10.1523\/JNEUROSCI.1794-11.2011","article-title":"Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated A\u03b2 is induced by pyroglutamate-A\u03b2 formation","volume":"31","author":"Alexandru","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2017.11.011_bb0010","doi-asserted-by":"crossref","first-page":"17338","DOI":"10.1038\/srep17338","article-title":"Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X","volume":"5","author":"Antonios","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.npep.2017.11.011_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S1474-4422(14)70301-1","article-title":"Alzheimer's disease and other dementias: advances in 2014","volume":"14","author":"Bateman","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.npep.2017.11.011_bb0020","doi-asserted-by":"crossref","first-page":"13222","DOI":"10.1038\/srep13222","article-title":"QIAD assay for quantitating a compound's efficacy in elimination of toxic Abeta oligomers","volume":"5","author":"Brener","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.npep.2017.11.011_bb0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer's disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.npep.2017.11.011_bb0030","doi-asserted-by":"crossref","first-page":"795375","DOI":"10.1155\/2014\/795375","article-title":"Amyloid beta: multiple mechanisms of toxicity and only some protective effects?","volume":"2014","author":"Carrillo-Mora","year":"2014","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"8","key":"10.1016\/j.npep.2017.11.011_bb0035","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/0269881111420313","article-title":"A comparison of InVivoStat with other statistical software packages for analysis of data generated from animal experiments","volume":"26","author":"Clark","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.npep.2017.11.011_bb0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-016-0115-2","article-title":"Immunotherapy targeting pyroglutamate-3 Abeta: prospects and challenges","volume":"11","author":"Cynis","year":"2016","journal-title":"Mol. Neurodegener."},{"issue":"10","key":"10.1016\/j.npep.2017.11.011_bb0045","doi-asserted-by":"crossref","first-page":"e0139710","DOI":"10.1371\/journal.pone.0139710","article-title":"Purification and characterization of recombinant N-terminally pyroglutamate-modified amyloid-beta variants and structural analysis by solution NMR spectroscopy","volume":"10","author":"Dammers","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.npep.2017.11.011_bb0050","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.bpj.2017.03.007","article-title":"Pyroglutamate-modified amyloid-beta(3-42) shows alpha-helical intermediates before amyloid formation","volume":"112","author":"Dammers","year":"2017","journal-title":"Biophys. J."},{"issue":"3","key":"10.1016\/j.npep.2017.11.011_bb0055","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/prot.340160309","article-title":"A comparison of the immunogenicity of a pair of enantiomeric proteins","volume":"16","author":"Dintzis","year":"1993","journal-title":"Proteins"},{"key":"10.1016\/j.npep.2017.11.011_bb0060","doi-asserted-by":"crossref","first-page":"19393","DOI":"10.1038\/srep19393","article-title":"Extracellular tau oligomers produce an immediate impairment of LTP and memory","volume":"6","author":"Fa","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.npep.2017.11.011_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000100355","article-title":"Amyloid-beta aggregation","volume":"4","author":"Finder","year":"2007","journal-title":"Neurodegener. Dis."},{"issue":"12","key":"10.1016\/j.npep.2017.11.011_bb0070","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1016\/j.neurobiolaging.2015.08.021","article-title":"An anti-pyroglutamate-3 Abeta vaccine reduces plaques and improves cognition in APPswe\/PS1DeltaE9 mice","volume":"36","author":"Frost","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"8","key":"10.1016\/j.npep.2017.11.011_bb0075","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1039\/b904138a","article-title":"Mirror image phage display\u2014a method to generate d-peptide ligands for use in diagnostic or therapeutical applications","volume":"5","author":"Funke","year":"2009","journal-title":"Mol. BioSyst."},{"issue":"6","key":"10.1016\/j.npep.2017.11.011_bb0080","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2174\/138161212799277752","article-title":"Peptides for therapy and diagnosis of Alzheimer's disease","volume":"18","author":"Funke","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"9","key":"10.1016\/j.npep.2017.11.011_bb0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1021\/cn100057j","article-title":"Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's disease transgenic mice","volume":"1","author":"Funke","year":"2010","journal-title":"ACS Chem. Neurosci."},{"issue":"12","key":"10.1016\/j.npep.2017.11.011_bb0090","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/cmdc.200800273","article-title":"Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A d-enantiomeric peptide identified by mirror image phage display","volume":"3","author":"van Groen","year":"2008","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.npep.2017.11.011_bb0095","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3233\/JAD-121792","article-title":"Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AbetaPP\/PS1 double transgenic mice","volume":"34","author":"van Groen","year":"2013","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.npep.2017.11.011_bb0100","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1006\/bbrc.2000.3490","article-title":"Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain","volume":"276","author":"Harigaya","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"45","key":"10.1016\/j.npep.2017.11.011_bb0105","doi-asserted-by":"crossref","first-page":"38825","DOI":"10.1074\/jbc.R111.288308","article-title":"Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease","volume":"286","author":"Jawhar","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.npep.2017.11.011_bb0110","doi-asserted-by":"crossref","first-page":"e0128553","DOI":"10.1371\/journal.pone.0128553","article-title":"Preclinical pharmacokinetic studies of the tritium labelled D-enantiomeric peptide D3 developed for the treatment of Alzheimer s disease","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.npep.2017.11.011_bb0115","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.bbamem.2016.07.002","article-title":"Blood-brain barrier penetration of an Abeta-targeted, arginine-rich, d-enantiomeric peptide","volume":"1858","author":"Jiang","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.npep.2017.11.011_bb0120","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jalz.2017.04.002","article-title":"Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability","volume":"13","author":"Kaniyappan","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.npep.2017.11.011_bb0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2016.04.016","article-title":"Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease","volume":"89","author":"Leithold","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.npep.2017.11.011_bb0130","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jocn.2003.12.007","article-title":"Alzheimer's disease pathogenesis and therapeutic interventions","volume":"11","author":"Parihar","year":"2004","journal-title":"J. Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.npep.2017.11.011_bb0135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s003359900551","article-title":"Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment","volume":"8","author":"Rogers","year":"1997","journal-title":"Mamm. Genome"},{"issue":"3","key":"10.1016\/j.npep.2017.11.011_bb0140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","article-title":"Development of AFFITOPE vaccines for Alzheimer's disease (AD)\u2014from concept to clinical testing","volume":"13","author":"Schneeberger","year":"2009","journal-title":"J. Nutr. Health Aging"},{"issue":"5257","key":"10.1016\/j.npep.2017.11.011_bb0145","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1126\/science.271.5257.1854","article-title":"Identification of D-peptide ligands through mirror-image phage display","volume":"271","author":"Schumacher","year":"1996","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.npep.2017.11.011_bb0150","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1006\/bbrc.1996.1413","article-title":"Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation","volume":"226","author":"Soto","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.npep.2017.11.011_bb0155","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/cbic.200300570","article-title":"Mirror-image phage display: aiming at the mirror","volume":"4","author":"Wiesehan","year":"2003","journal-title":"Chembiochem"},{"issue":"53","key":"10.1016\/j.npep.2017.11.011_bb0160","doi-asserted-by":"crossref","first-page":"41517","DOI":"10.1074\/jbc.M110.178707","article-title":"Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis","volume":"285","author":"Wirths","year":"2010","journal-title":"J. Biol. Chem."}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417917301531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417917301531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T11:42:52Z","timestamp":1530186172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417917301531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":32,"alternative-id":["S0143417917301531"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2017.11.011","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A\u03b2 oligomer eliminating compounds interfere successfully with pEA\u03b2(3\u201342) induced motor neurodegenerative phenotype in transgenic mice","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2017.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}